JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

JNJ

238.34

-0.13%↓

UNH

275.18

+0.24%↑

TMO

547.45

+1.67%↑

ABT

111.8

+1.4%↑

ISRG

498.29

+2.04%↑

Search

Baxter International Inc

Aperta

SettoreSettore sanitario

21.95 2.24

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.09

Massimo

22.05

Metriche Chiave

By Trading Economics

Entrata

-173M

-51M

Vendite

25M

2.8B

P/E

Media del settore

86.308

84.243

Rendimento da dividendi

3.39

Margine di Profitto

-1.799

Dipendenti

38,000

EBITDA

-46M

416M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+1.89% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.39%

2.28%

Utili prossimi

12 feb 2026

Prossima data del Dividendo

31 mar 2026

Prossima data del' Ex Dividendo

27 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.7B

10B

Apertura precedente

19.71

Chiusura precedente

21.95

Notizie sul Sentiment di mercato

By Acuity

37%

63%

103 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Baxter International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 feb 2026, 17:25 UTC

Acquisizioni, Fusioni, Takeovers

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9 feb 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9 feb 2026, 23:43 UTC

Discorsi di Mercato

Gold Falls on Possible Technical Correction -- Market Talk

9 feb 2026, 23:14 UTC

Discorsi di Mercato

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9 feb 2026, 22:29 UTC

Discorsi di Mercato

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9 feb 2026, 22:19 UTC

Discorsi di Mercato

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9 feb 2026, 22:08 UTC

Discorsi di Mercato

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9 feb 2026, 22:01 UTC

Utili

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9 feb 2026, 21:59 UTC

Utili

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9 feb 2026, 21:59 UTC

Utili

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9 feb 2026, 21:58 UTC

Utili

Friedman Industries 3Q Sales $168M >FRD

9 feb 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

9 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 feb 2026, 21:48 UTC

Utili

Friedman Industries 3Q EPS 43c >FRD

9 feb 2026, 21:17 UTC

Utili

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9 feb 2026, 21:13 UTC

Discorsi di Mercato

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9 feb 2026, 21:04 UTC

Utili

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9 feb 2026, 20:30 UTC

Discorsi di Mercato

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9 feb 2026, 20:02 UTC

Discorsi di Mercato

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9 feb 2026, 19:42 UTC

Discorsi di Mercato

Japan's Yield Curve Expected to Flatten -- Market Talk

9 feb 2026, 19:31 UTC

Discorsi di Mercato

Nike Seen Regaining Relevance With Consumers -- Market Talk

9 feb 2026, 19:27 UTC

Discorsi di Mercato

Gold Climbs Back Over $5,000/oz -- Market Talk

9 feb 2026, 19:05 UTC

Discorsi di Mercato

Nike Returns to List of Hottest Brands -- Market Talk

9 feb 2026, 18:19 UTC

Discorsi di Mercato

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9 feb 2026, 17:41 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9 feb 2026, 17:31 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9 feb 2026, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

9 feb 2026, 17:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 feb 2026, 17:17 UTC

Discorsi di Mercato

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9 feb 2026, 17:16 UTC

Utili

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Baxter International Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.89% in crescita

Previsioni per 12 mesi

Media 22.14 USD  1.89%

Alto 30 USD

Basso 15 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Baxter International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

7 ratings

2

Acquista

4

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

30.475 / 31.345Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

103 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
help-icon Live chat